SF3A3 Promotes Hepatocellular Carcinoma Progression and Regulates Jagged 2–Notch 1 Signaling
ABSTRACT Splicing factor 3a subunit 3 (SF3A3) has been reported to be dysregulated in various cancers. Previous studies have suggested its prognostic value in hepatocellular carcinoma (HCC), but the specific effect and molecular mechanisms remain to be further explored. Therefore, this study aims to investigate the role of SF3A3 in HCC pathogenesis. SF3A3 expression was compared between HCC and normal tissues using public databases and immunohistochemistry, and its clinical significance was evaluated by clinicopathological, ROC, and Kaplan–Meier analyses. Differential expression and enrichment analyses explored potential biological functions. In vitro assays assessed the effects of SF3A3 knockdown on HCC cell proliferation, migration, and invasion. RNA sequencing, molecular validation, and rescue experiments investigated the underlying mechanism, while a nude mouse xenograft model evaluated its role in vivo. SF3A3 was significantly upregulated in HCC and was associated with adverse clinicopathological features. SF3A3 expression showed discriminatory ability between HCC and normal liver tissues in retrospective transcriptomic cohorts and was associated with poor survival. Functional enrichment analyses linked SF3A3 to cell cycle regulation and DNA replication, while SF3A3 knockdown suppressed HCC cell proliferation, migration, and invasion in vitro. Transcriptomic profiling further identified Notch signaling as a potential downstream pathway, and this association was supported by rescue experiments. In conclusion, SF3A3 promotes tumor progression and is associated with regulation of Jagged 2–Notch 1 signaling. These findings provide preliminary insight into the molecular mechanisms underlying SF3A3‐mediated HCC progression and support further investigation of its potential clinical and therapeutic relevance.
Authors
- 周光文
- Luyang Liu (ORCID: https://orcid.org/0000-0002-3462-5135)
- Jing Yang (ORCID: https://orcid.org/0009-0003-6251-6387)
- Yan Zhang
Institutions
- Shanghai Jiao Tong University (CN)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Shanghai Sixth People's Hospital (CN)
- Chirurgische Universitätsklinik Heidelberg (DE)
Publication Details
- Journal
- Molecular Carcinogenesis
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1002/mc.70204
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00